



EXTRACTION AND QUALITATIVE ESTIMATION OF ZOLPIDEM IN SPIKED SAMPLES: A REVIEW

Khushboo

Assistant professor, Saraswati College of Pharmacy, Pin code: 140413, Email id: kg977280@gmail.com,

Orcid id: 0009-0001-7028-7110

Received:- 02-07-2026 Revised:- 20-08-2026 Acceptance:- 17-09-2026 Published:- 06-10-2026

Abstract

Being a portion of the Z-drugs class, zolpidem is a pharmacological compound applied to address sleeplessness that is not benzodiazepine-derived. Zolpidem is marketed in America under the proprietary name Ambien®. In Europe and the USA, there are two short-acting hypnotic medications called Zaleplon. Aside from drugged driving, this prescription drugs are often claimed as an instrument in drug-facilitated crimes such robberies, extortions, and date rape. Gas Chromatography-Mass Spectrometry technique using ether extraction in one step. The approach that was published proved to be inexpensive, sensitive, quick, and appropriate for analyzing spiked meals and drinks as well as urine for signs of robbery, sexual assault, or purposeful or inadvertent drunkenness. The drugs were extracted from the spiked samples using methanol and analyzed using LC-MS/MS. Worldwide, zolpidem and benzodiazepines are often abused and misused. They are frequently abused in crimes and their unlawful distribution has led to a substantial increase in their abuse.

Keywords: Zolpidem; Zaleplon; Benzodiazepines; drug facilitated crimes; Gas chromatography-mass spectrometry (GC-MS); Liquid chromatography-mass spectrometry (LC-MS).

1. Introduction

Z Pills, often called non-benzodiazepines, are psychoactive drugs that doctors use to treat a range of sleep disorders. Additionally, it is used to promote relaxation, ease muscular tension, and reduce anxiety. Their natural qualities resemble those of benzodiazepines. Nonbenzodiazepine is molecularly unrelated to benzodiazepines since they exhibit different or entirely separate chemical characteristics from them. Three molecular classes comprise non-benzodiazepines. Criminals are drawn to non-benzodiazepines due of their accessibility and beneficial combination with alcohol. They are highly susceptible to inducing hypnosis, anterograde amnesia, and muscular relaxation. Some indicators of an overdose include ataxia, poor balance, slurred speech, and depression in the central nervous system (CNS). These qualities make it a potent tool that criminals use to steal, harass sexually, and kill unsuspecting men and women by spiking their drinks at pubs and bars (Gunzerath et al., 2004; Tsujikawa et al., 2005). Both drug-facilitated crime (DFC) and drug-facilitated sexual assault (DFSA) are on the rise everywhere, including in India. The availability of non-benzodiazepines and their beneficial interactions with alcohol make them attractive to criminals. They frequently experience anterograde amnesia, hypnosis, and muscular relaxation induction. An overdose manifests as ataxia, slurred speech, depression in the CNS, and impaired balance. It is a potent tool that criminals use to spike the drinks of gullible men and women at pubs and bars so they may subsequently rob, sexually abuse, or kill them (Parast et al., 2018; Forsman et al., 2009). There are two well-known brands: Xanax and Valium. These are among the most extensively prescribed drugs in the US. Harassment occurs when non-prescription users obtain these drugs and utilize them for their sedative properties. Benzodiazepines have been utilized as a date assault sedate since they may extremely diminish and indeed annul capacities that regularly energize an individual to dodge or indeed wish to contradict sexual badgering or ambush. The amount of those people who have been confined and convicted for this offense has significantly increased in recent years. The chemical, which has a strong flavor, is frequently added to alcoholic beverages or even soft drinks in liquid or powder form (Sarin and Feng, 2019). Benzodiazepines have various activities on the gamma-amino butyric acid (GABA) synapse at the GABA receptor, including anxiolytic, hypnotic, muscle relaxant, and anticonvulsant properties. High dosages of certain of the most selectively acting benzodiazepines may potentially result in dissociation and anterograde amnesia. Benzodiazepine use can have long-term negative repercussions, such as emotional and social problems and mental decline. It is possible to suffer feelings of choppiness, an inability to think clearly, a lack of sex desire, agoraphobia and social anxiety, fear and discouragement, a loss of confidence in one's ability to engage in sports and hobbies, and difficulties experiencing or expressing emotions (Acikkol, 2009; Xiang et al., 2012). The use of drugs to manipulate behavior for illicit ends is not a recent development. A frequent occurrence in drug-facilitated crime instances is the spiking of psychoactive chemicals, such as benzodiazepines, ketamine, barbiturates, and Z-drugs, into drinks and food items (Soltaninejad et al. 2016; Kantarcu et al., 2012; and Cheze et al., 2004). These drugs are frequently utilized to calm down victims of crimes like robbery and sexual assault (Lin et al., 2014; Afandiyev et al., 2017; Yamaguchi et al., 2021). Furthermore, these compounds are under the purview of forensic toxicology, since they might result in drug-induced impairment in driving as well as purposeful or inadvertent poisoning (Jönsson et al., 2014; Gunja et al., 2013). The Z-drugs, zolpidem, zopiclone, and zaleplone, are widely employed to alleviate sleeplessness instead of benzodiazepines. Due to its mild adverse effects the day after, zolpidem is the most favored Z-drug (Keller et al., 1999). It also contains mild muscle relaxant, anxiolytic, and anticonvulsant qualities additionally to treating insomnia (Sanger et al., 1998; Bramley et al., 2005). Following consumption, zolpidem is quickly taken in from the gastrointestinal system. Its effects on the CNS are demonstrated by the gamma aminobutyric acid (GABA)-A agonist receptor (Drover, et al., 2000). Following consumption, the liver's CYP3A4 and CYP2C9 enzymes transform zolpidem into two pharmacologically inactive metabolites (Salva, 1995). One of the most often recommended drugs for treating insomnia is zolpidem, additionally referred to as Ambien in Europe (Olubodun, 2003). The American FDA, or the Food and Drug Administration authorized both Ambien in 1993 and Stilnox in 1986 to be utilized in Europe (Meeker, 1995). The FDA medication list lists zolpidem as a restricted substance as well; it is categorized as the fourth drug class and is used to treat

insomnia that lasts less than a month (Park, 2016). When zolpidem is included in food or drink, it has no impact on the substance's appearance or flavor. In this regard, it might be challenging for the victim of a drug-facilitated crime to detect the taste or smell of the substance. Furthermore, zolpidem can metabolize up to 70% of its initial dosage within a few hours after use (Clerck, 1997). Better division is provided by High-Performance Thin Layer Chromatography (HPTLC), a more sophisticated kind of thin layer chromatography (TLC). The definition of HPTLC includes assessing methods that have been demonstrated to be both qualitative and quantitative, additionally satisfying all consistency requirements for usage under complete supervision. The kind of material, chromatogram growth, or detection has no bearing on HPTLC. Compared to other chromatographic techniques, HPTLC offers the following benefits such as Saves inspection time, only takes 3 to 20 minutes for good division. Recognition is 5 to 10 times better than conventional TLC. Quantitative assessment requires precise and highly reproducible clustering. Easily incorporated into biological assays, making it particularly suitable for analysis of synergistic effects. Once evaluated, specific areas can be subjected to mass spectrometry (MS), thereby eliminating the need to record every scan, including mesh and foundation (Soltaninejad et al., 2016; Touma et al., 2024).

Zolpidem is extracted from biological materials and drinks using a variety of analytical techniques, including electrophoresis, GC-MS, LC-MS/MS, and HPLC. Furthermore, zolpidem has grave adverse effects that might occur in coma and death in situations of intentional or accidental poisoning, particularly when paired with additional drugs or alcohol. For this reason, it is a substance that has to be considered in antemortem and postmortem forensic toxicology (Cheze et al., 2004). As far as we are aware, no documented method utilizing GC-MS has been established as a standard analytical technique in forensic toxicology laboratories for either biological materials or drinks in our nation. When using the validated technique to investigate zolpidem when spiked in food and drinks, various performance factors such as extraction efficiency, detection limit, linearity, and precision were considered (Bramley et al., 2005).

Molecular structure of Zolpidem and their adverse effects on body





Figure: Chemical Structure of Zolpidem (Smyth et.al. 2015)

Sr.No.	Parts of Chemical structure of Zolpidem	Their structure	Their Role	Adverse Effects on Body	References
1.	Imidazopyridine ring	Imidazo[1,2-a]pyridine (Sanapalli et.al.,2022)	Essential for pharmacological activity as sedative hypnotic reagents (Smith et.al. 2023).	This ring shape is essential to the medication's effectiveness, but it can also lead to side effects like fatigue, vertigo, and poor coordination.	Sanapalli et al., 2022; Smith et al., 2023; Smith et al., 2020.

				The CNS drowsiness and decreased cognitive function caused by zolpidem are the main causes of these symptoms (Smith et al., 2020).	
2.	Methyl Group	R - CH ₃	Zolpidem contains a methyl group attached to the imidazole ring.	Although the methyl group makes zolpidem more selective for certain GABA-A receptor subunits, it can also intensify CNS	Smith et al., 2022



Some common Consequences of Zolpidem

Mechanism of Action

One substance that is not a benzodiazepine is zolpidem exerts rapid-onset and short-lasting hypnotic effects via interacting with benzodiazepine receptors, especially within the cerebellum, showing a more robust preference for binding stronger with BZ (ω) receptors. The BZ (ω) binding sites are associated with the GABAA receptor subtype, a ligand-gated ion channel with five subunits for neurotransmitter that inhibits GABA (Pritchett et al., 1994). Low zolpidem concentrations improve GABA effects, indicating that zolpidem binds preferentially to BZ (ω) receptors containing the $\alpha 1$ subunit, unlike benzodiazepines, which bind to all BZ subtypes indiscriminately. On the other hand, greater zolpidem concentrations are needed to intensify GABA's actions on receptors that include $\alpha 2$ and $\alpha 3$ subunits. At receptors containing $\alpha 5$, there was minimal or no reaction (Wafford et al., 2009). The actions of zolpidem, which include sedation, anticonvulsant, anxiolytic, and muscle relaxant, are partially attributed to subunit binding to the GABAA receptor (Rogers, 2024). The lamina IV of the brain's sensorimotor cortex, the substantia nigra pars reticulata, the cerebellum's molecular layer, <http://eijas.com/index.php/as>

the olfactory bulb, the ventral cortex, the pons, the inferior pons, and the sphere haggard are the primary locations for BZ (ω) receptors. At high dosages, zolpidem causes only brief rapid wave periods (12 to 14 Hz) on the EEG in addition to slow waves (2 to 4 Hz). Compared to benzodiazepines, which cause greater amounts of rapid wave activity that are inconsistent with regular sleep patterns, this impact is preferable. Electroencephalography in cats and rats has verified zolpidem-induced increases in slow- or non-rapid-wave eye movement sleep. Except at high dosages, zolpidem in these trials enhanced non-REM sleep while having minimal effect on REM sleep (Zhang et al., 2022).

Schematic Representation of Mechanism of Action

Pharmacodynamics

The sedate zolpidem, an imidazopyridine, is utilized to treat determined sleep deprivation, a condition checked by inconvenience falling snoozing and/or remaining sleeping. It's imperative to remember that zolpidem is fundamentally distinctive from benzodiazepines. Zolpidem upgrades the chemical that inhibit γ -aminobutyric acid (GABA) movement by specific agonist at the BZ1 receptor. This comes about in expanded chloride conductivity, neuronal and restraint of the activity potential, which by and large diminishes neuronal volatility and results in the narcotic and sleep inducing impacts seen whereas taking this medicine (Santiago et al., 2013). Since zolpidem is specific for the BZ1 receptor $\alpha 1 / \alpha 5$ subunits compared to the BZ2 receptor location. It shows negligible anxiety, muscle relaxant and anticonvulsant side impacts related with agonist at the BZ2 receptor location (Bramley et al., 2005). The predominance of BZ1 receptor on structures basic for coordinating rest, tallying Layer IV of the sensorimotor cortical area, the substantia nigra (reticular formation), the nuclear layer of the cerebellum, the olfactory bulb, the ventral thalamic complex, the pons, the colliculus of the moment rate and the globus pallidus.

Pharmacokinetics

Biphasic absorption is exhibited by zolpidem, it implies that it is rapidly absorbed in the gastrointestinal system at first and has prolonged plasma concentrate on more than three hours following delivery. Zolpidem is mostly metabolized by CYP3A4 enzymes, with enzymes CYP2C9, CYP1A2, CYP2D6, and CYP2C19 having a smaller role (Zhang et al., 2022). After conversion to inactive metabolites, zolpidem is mostly excreted via the kidneys (Bramley et al., 2005). The zolpidem plasma exposure is unaffected by the CYP2C9*1/*3 genotype (Zhanget al., 2022). Research on the effects of food on behavior has revealed that taking zolpidem just after eating is connected to a quicker start of sleep (Touma, 2024). People on the regimen have reported good levels of daytime alertness, and zolpidem has not demonstrated any rebound or withdrawal symptoms (Bramley, 2005). Oxidation and hydroxylation are the medication's principal metabolic pathways (Touma et al., 2024). The percentage of zolpidem that is bound to plasma proteins is about 92%, and its total bioavailability is about 70% (Touma et al., 2024; Bramley et al., 2005). Individuals with hepatic and renal impairment should take zolpidem at lower dosages, and those who previously zolpidem or any other inert chemicals within the composition should avoid taking it at all (Zhang et al., 2022). It hasn't been shown that the Coadministration of digoxin, warfarin, or haloperidol affects the zolpidem is metabolized. Patients using Flumazenil, however, should exercise caution since it negates zolpidem's hypnotic effects. Furthermore, studies have shown that participants receiving zolpidem + imipramine experienced anterograde amnesia (Kong et al., 2022). Children have a three-fold higher clearance of zolpidem than young adults, and the elderly have a lower clearance. Therefore, zolpidem dosages for senior people should be reduced. Elderly people benefit from zolpidem dose reductions since their symptoms of persistent insomnia are more likely to manifest in them. Above all, people are more likely to suffer adverse effects from medications that impact the central nervous system (Santiago et al., 2013; Hoehns et al., 1993). Additionally; Studies have shown that when zolpidem is stopped, the likelihood of rebound insomnia is reduced. The pharmacokinetic parameters do not significantly differ across genders and different racial groupings (Cole et al., 2020; Griswold et al., 2018).

Analytical Aspect of zolpidem

Pitrowaski et al. 2015 studied on typically, benzodiazepines and zolpidem are prescribed as anticonvulsants, hypnotics, sedatives, or anxiolytics. Nonetheless, these medications are commonly

abused in drug-facilitated crimes. Consequently, utilizing deuterium labeled internal standards (IS), a quick and easy liquid chromatography–tandem mass spectrometric (LC–MS/MS) approach was created for the identification and measurement of benzodiazepines, zolpidem, and their metabolites in urine. After combining 120 μL of urine with 80 μL of the IS solution, the mixture was centrifuged. In order to perform analysis, the LC–MS/MS apparatus was immediately injected with a 5 μL aliquot of the sample solution. Water and acetonitrile with 0.2% acetic acid and 2 mM ammonium trifluoroacetate made up the mobile phases. Agilent's Zorbax SB-C18 (100 mm $\times$ 2.1 mm i.d., 3.5 μm) used as the analytical column. In less than ten minutes, eighteen analytes had been separated and detected. The calibration curves demonstrated linearity across concentration ranges of 0.5–20 ng/mL for zolpidem, 1.0–40 ng/mL for temazepam and flurazepam, 2.5–100 ng/mL for 7-aminoclonazepam, 1-hydroxymidazolam, midazolam, flunitrazepam, and alprazolam, 5.0–200 ng/mL for zolpidem, phenyl-4-carboxylic acid, α -hydroxyalprazolam, oxazepam, nordiazepam, triazolam, diazepam, and α -hydroxytriazolam, 10–400 ng/mL for lorazepam and desalkylflurazepam, and 10–100 ng/mL for N-desmethylflunitrazepam. The coefficients of determination (r^2) were above 0.9971. The analytes' dilution integrity was looked in to supplement with short linear range. Using two, four, and ten-fold dilutions, dilution precision and accuracy were measured; the results ranged from 3.7 to 14.4% and –12.8 to 12.5%, respectively. This method's process efficiency ranged from 63.0 to 104.6%. Less than 11.8% and 9.1% were the intra- and inter-day precisions and less than –10.0 to 8.2% were the intra- and inter-day accuracies, respectively. For every analyte, the quantitative Lower bounds were not as high as 10 ng/mL. Human urine samples from 21 drug users were used to successfully verify the suggested method's applicability. For easy sample preparation and high sensitivity with the necessary separation, direct urine sample injection and improved mobile phases were introduced (Pitrowski et al., 2015).

Elishabeth Leere et.al. Determining the amount of these medications in peripheral blood (PB) may be crucial in determining the cause of death. However, in certain forensic examinations, PB is not accessible. To ascertain if the concentrations of benzodiazepines and z-hypnotics in five different matrices are similar to the concentrations in PB, the current study compared such values. There were 109 forensic autopsy cases in all. Using tandem mass spectrometry and ultra-high performance liquid chromatography, PB, cardiac blood (CB), pericardial fluid (PF), psoas muscle (PM), lateral vastus muscle (LVM), and vitreous humor (VH) from each instance were examined. In all of the investigated matrices, we managed to recognize clonazepam, 7-aminoclonazepam, flunitrazepam, 7-aminoflunitrazepam, nitrazepam, 7-aminonitrazepam, diazepam, nordiazepam, oxazepam, alprazolam, midazolam, zopiclone, and zolpidem. Apart from zopiclone, concentrations detected in VH were often substantially less than those in PB. Although not as high as for the parent chemicals, 7-amino metabolite quantities were nevertheless present in the muscle samples. While the concentrations of the other chemicals in muscle exhibited good correlation with PB, the concentrations of the parent nitrobenzodiazepines in muscles compared to PB were higher. However, there was still more variation and a propensity for higher concentrations in PF, both CB and PF were good substitute matrices for PB (Ishida et al., 2009).

Reidy, et.al. (2008) conduct the study that the non-benzodiazepine hypnotic drug zolpidem (Ambien®) was authorized for use in the US in 1993 for the short-term management of insomnia. Because of its quick start of action and short half-life of elimination, zolpidem is a great sleep aid. This investigation sought to evaluate and compare the efficacy of gas chromatography-mass spectrometry (GC-MS) and the Immualysis® ELISA kit in screening blood and urine specimens for zolpidem. Furthermore, the occurrence of zolpidem among drivers suspected of driving under the influence in 2007 is contrasted with statistics from prior years. The cross-reactivity of the ELISA kit with zolpidem metabolite I, zaleplon, and zopiclone was assessed. After an alkaline liquid-liquid extraction, 100 urine samples and 100 blood samples were selected from specimens delivered to the DUI laboratory in 2007. The specimens were examined on GC-MS in full EI scan mode with the Immualysis Zolpidem ELISA kit. As stated by the results, 5% of the urine and blood samples had positive results for zolpidem using ELISA kits, and all 5% of those samples had zolpidem confirmed positive using GC-MS. The ELISA kit failed to display any cross-reactivity with zaleplon or zopiclone at 1000 ng/mL of spiked urine. A greater incidence rate than in previous years was seen in 2007, with ten cases of suspected DUI drivers having their blood or urine tested positive for

zolpidem by ELISA and GC-MS. Owing to the poor percentage clearance of the parent chemical in urine, a screening approach for zolpidem's principal metabolite may be required in order to more precisely identify drug impairment driving (Reidy et al., 2008).

Driving under the influence

DUI is an increasing issue for public safety. Evaluation of driving impairment due to medications may be challenging for forensic practitioners as many factors need to be regarded as the person's physiological condition, drug use history, the type and dose of drug(s) and drug-drug interaction. The potential for zolpidem to interfere with driving, behavior, and cognitive abilities is assessed when it is used or misused. Compared to other drugs, zolpidem hampered coordination and cognitive abilities more quickly (James et al., 1952). The effect of zolpidem was studied by Jones and Holmgren (Sparkman et al., 2011). They determined the concentrations of zolpidem and zopiclone in peripheral blood samples taken from individuals who are still alive (impaired drivers) and in femoral blood from deceased persons collected over a 10-year period (2001–2010). Zolpidem median concentration (0.30 mg/L) was found in intoxication deaths (N = 357) compared with 0.13 mg/L for other causes of death (N = 397) or 0.19 mg/L in impaired drivers (N = 837) ($p < 0.001$). The median concentrations of zolpidem in blood decreased among in congested cases and increased for poisoning fatal cases. The most frequent co-ingested substances were ethanol in fatal cases and diazepam in the drivers (Pitt et al., 2009; Eagon et al., 2010).

In a different research, Favretto et al. examined 4066 blood samples collected from drivers in accidents in the Italian region of Padova to look for the presence of sedative-hypnotic substances, alcohol, and prescription medications. Of these, 175 blood samples that revealed positive results for sedative-hypnotic medications at concentrations more than 1 ng/mL. There was zolpidem found in 28% of the samples. They came to the conclusion that sedative-hypnotics, such as zolpidem, are medications that are regularly found in drivers involved in auto accidents, usually in amounts linked to driving under the influence (Logan et al., 2001; Hasegawa et al., 2018).

In research, Booth et al. evaluated the association between current use of zolpidem-containing medications and motor vehicle collisions (MVCs) among 2000 very old drivers aged ≥ 70 years residing in north-central Alabama, USA with current zolpidem use. They concluded that the current zolpidem users, specifically women and individuals aged ≥ 80 years, had higher MVC rates than nonusers (Doane et al., 2008). Also, previously described that zolpidem has an additive effect of alcohol in the driving impairing effects. The performance skills tested including divided attention, memory and data processing rate indicated an additive impairment effect with alcohol and zolpidem (Augsburger et al., 1993; Pitt et al., 2009).

Kwon and Han examined drug usage in recently documented instances of drug-impaired driving (DUID) in Asia, the United States, and Europe. They revealed that reports of ketamine, morphine, methamphetamine, and khat were common across Asia. Synthetic cannabinoids, opiates, and cocaine were recorded in Europe, whereas amphetamine, benzodiazepines, and Z-drugs, which include zolpidem and cannabinoids, were primarily reported in the USA (Prabhavale et al., 2016).

Drug Facilitated Sexual Assault

The increase of drug-facilitated crimes (sexual assault, robbery, kidnapping, homicide) is considered as a serious general public security problem. Drugs involved can be pharmaceuticals including benzodiazepines (diazepam, flunitrazepam, lorazepam, etc.), z-drugs (zolpidem, zopiclone, zaleplon), sedatives (neuroleptics, some antihistamine H1-blockers) or anaesthetics (γ -hydroxybutyrate, ketamine), muscle relaxants (Baclofen, carisoprodol), drugs of abuse, such as cannabis, ecstasy or lysergic acid diethylamide (LSD), or mainly ethanol (Pitt et al., 2009). DFSA is regarded as a subcategory of drug-facilitated crimes. DFSA is characterized as the incidence wherein a person (male or female), is subjected to engaging in sexual activity when they are incapacitated or unconscious due to the ingestion of ethanol or any other intoxicating substance, resulting in the inability to resist or consent to such acts (Gock et al., 1999). Zolpidem is considered as a promoter of sexual assault, because of its rapid onset of action, effectiveness to induce and maintain sleep/unconsciousness, and anterograde amnesia are all attributes commonly seen in drugs used in DFSA (Kantaraci et al., 2012).

Carfora et al. reported a 56-year-old female tourist claimed to have been sexually assaulted by five

men after having had a drug-spiked alcoholic beverage. After seven months, hair strands were also sampled to perform the segmental hair analysis. Gas chromatography–mass spectrometry (GC-MS) and liquid chromatography–tandem mass spectrometry (LC-MS/MS) techniques were applied for the qualitative and quantitative analyses. Zolpidem (concentration range: 0.70– 1.06 pg/mg), flunitrazepam and oxazepam were detected in the hair segments corresponding to the time frame of the alleged rape (Carfora et.al., 2018).

Hasegawa, k, et.al (2018) detailed a case that a man in his 20s gave himself an intravenous measurements of zolpidem. The man had new infusion scars on his right lower arm and a tourniquet band around his neck when he was found dead on the floor of his level. A restorative transfer syringe with a small-volume arrangement that broken down pulverized zolpidem pills was found following to the body. Asphyxia coming about from stomach substance suctioning into the trachea and bronchi was decided to be the coordinate cause of his passing. Among the things analyzed were body fluids and solid tissues, checking pericardial fluid, pee, bile, stomach substance, brain, lung, heart muscle, liver, spleen, kidney, pancreas, and skeletal muscle. Femoral vein blood was in addition attempted. An adjusted QuEChERS strategy was utilized to extricate zolpidem, zolpidem phenyl-4-carboxylic corrosive and deuterated inside benchmarks, and zolpidem-d7 and zolpidem phenyl-4-carboxylic acid-d4. Fluid chromatography–tandem mass spectrometry was at that point utilized for investigation. The truth that this ponder included a extend of human frameworks with to some degree changing quality implied that the conventional expansion approach was the foremost productive implies of overcoming network impacts and recuperation rates. It too dispensed with the necessity for clear human networks to be utilized in approval ponders. The comes about of the tests on the distinctive examples appeared that the perished had passed on from an intravenous zolpidem infusion since the amounts of zolpidem and its metabolite, phenyl-4-carboxylic corrosive, were frequently even more noticeable than those of lethal occurrences that had been recorded. The show case's femoral vein blood and cleared out and right heart blood examples had zolpidem values of 9.55, 28.5, and 46.9 µg/mL, respectively—much higher than the anticipated deadly edge. The dissemination and redistribution of zolpidem and its metabolite, phenyl-4-carboxylic corrosive, in 15 real liquid and strong tissue examples, counting the substance of the stomach, were too illustrated in this examination. Whereas prior distributed literary works managed with zolpidem harming cases emerging from verbal medicine organization (Hasegawa et al., 2018), this is often the primary report on a lethal intravenous zolpidem infusion case and the after death conveyance of zolpidem and its essential metabolite (Acikkol et al., 2009).

Prabhavale et.al. (2016) conduct the case study on a lady who claimed to have existed drugged and abused. She had claimed to have been given certain drugs under duress, which caused her to lose consciousness. The blood sample and the woman's saree were brought into the laboratory. Some white streaks that seemed to be vomit were discovered on the saree upon closer examination. It turned out that zolpidem had been used after samples from these stains and tests on blood samples were performed for the presence of several medications. The methods used in this work to study zolpidem include HPTLC, UV, HPLC, and GC-MS. Dragendorff's reagent is sprayed onto the HPTLC plate, which displays an orange colored spot at the R_f value of 0.4, along with the solvent system used for HPTLC, which is chloroform: ethyl acetate: acetone (8:1:1). When the new approach was used on biological material, positive outcomes were seen (Prabhavale et al., 2016).

Conclusion

Z Pills, often referred to as non-benzodiazepines, are psychoactive drugs that doctors use to treat a range of sleep disorders. Criminals are drawn to non-benzodiazepines due of their accessibility and beneficial combination with alcohol. They are highly susceptible to inducing hypnosis, anterograde amnesia, and muscular relaxation. Ataxia, impaired balance, slurred speech, and depression in the CNS are among the signs of an overdose. These qualities make it a potent tool that criminals use to steal, harass sexually, and kill unsuspecting men and women by spiking their drinks at pubs and bars. The chemical, which has a strong flavor, is frequently added to alcoholic beverages or even soft drinks in liquid or powder form. A frequent occurrence in drug-facilitated crime instances is the spiking of psychoactive chemicals, such as benzodiazepines, ketamine, barbiturates, and Z-drugs, into drinks and food items. The Z-drugs, zolpidem, zopiclone, and zaleplone, are frequently used to

treat insomnia instead of benzodiazepines. Due to its mild adverse effects the day after, zolpidem is the most favored Z-drug. When zolpidem is added to food or drink, it has no effect on the substance's appearance or flavor. Furthermore, zolpidem can metabolize up to 70% of its initial dosage within a few hours after use. Better division is provided by HPTLC, a more sophisticated kind of TLC. The definition of HPTLC includes methods of measurement that have been demonstrated to be both qualitative and quantitative, additionally satisfying all consistency requirements for usage under complete supervision. Zolpidem is extracted from biological materials and drinks using a variety of analytical techniques, including electrophoresis, GC-MS, LC-MS/MS, and HPLC. Furthermore, zolpidem has serious negative effects that may result in coma and death in situations of intentional or accidental poisoning, particularly when paired with additional drugs or alcohol. Regarding we are aware, no documented method utilizing GC-MS has been established as a standard method of analysis used in forensic toxicology labs for either biological materials or drinks in our nation.

Future Perspectives

When discussing the removal of zolpidem and its qualitative examination in spiked samples, it is crucial to take into account current trends and future developments in analytical chemistry techniques. A typical prescription drug used to temporarily treat insomnia is zolpidem. To be able to analyze zolpidem in spiked samples, the active ingredient must first be extracted from the sample matrix and then its presence qualitatively determined using an analytical method (Chen et al., 2023). **Sample Preparation Techniques:** Conventional test planning strategies such as liquid-liquid extraction (LLE) and solid-phase extraction (SPE) are broadly utilized to extricate zolpidem from natural materials. Still, there's a developing development to create greener and more compelling extraction strategies. The improvement of microextraction strategies such as pressed sorbent microextraction (MEPS) and strong phase microextraction (SPME) may be a future advancement, advertising focal points such as diminished dissolvable utilization, shorter extraction times, and expanded affectability (Zhang et al., 2022)

Advanced chromatography techniques: Chromatography is frequently applied to qualitative analysis of zolpidem due to its high sensitivity and selectivity. The most commonly used methods High-performance liquid chromatography (HPLC) in combination with ultraviolet (UV) or mass spectrometry (MS) detection. The development of portable or compact chromatography equipment for on-site analysis and the use of state-of-the-art stationary phase and column technologies to improve separation efficiency and resolution are potential future developments in chromatography technology (Wang et al., 2022).

Mass spectrometry (MS) detection: Mass spectrometry is a useful technique for qualitative examination of zolpidem due to its high sensitivity and specificity. The development of ion mobility spectroscopy and high-resolution mass spectrometry, additionally other developments in MS methods, which might enable more accurate identification and characterization of zolpidem in complex sample matrices. Furthermore, the combination of MS and chromatographic techniques (e.g., LC-MS/MS) allows simultaneous quantification and confirmation of zolpidem in spiked sample (Zhang et al., 2023).

Overview of future perspectives

New analytical techniques: For the qualitative analysis of zolpidem, there is great interest in creating fresh methods of analysis that go beyond traditional mass spectrometry and chromatography methods. For example, ambient ionization mass spectrometry methods, such as direct real-time analysis (DART) mass spectrometry and Mass spectrometry using DESI, rapidly detect zolpidem in spiked materials without requiring sample preparation. And can be analyzed non-destructively (Zhang et al., 2023).

The development and integration of advanced sample preparation techniques, chromatographic methods, mass spectrometry instrumentation, and data analysis techniques to improve sensitivity, selectivity, and efficiency in the identification and quantitation of zolpidem in complex sample matrices.

References

1. Gunzerath, L., Faden, V., Zakhari, S., & Warren, K. (2004). National Institute on Alcohol Abuse and Alcoholism report on moderate drinking. *Alcoholism: Clinical and Experimental Research*.
2. Parast, L., Tran, H., & Moore, A. A. (2018). Identifying adolescents with alcohol use disorder: Optimal screening using the National Institute on Alcohol Abuse and Alcoholism screening guide. *Psychology of Addictive Behaviors*.
3. Sarin, R. K., Sharma, N., & Bhatia, A. Determination of diazepam in cold drinks by high-performance thin-layer chromatography.
4. Acikkol, M., Mercan, S., & Karadayi, S. (2009). Simultaneous determination of benzodiazepines and ketamine from alcoholic and nonalcoholic beverages by GC-MS in drug facilitated crimes. *Chromatographia*, 70, 1295-1298.
5. Soltaninejad, K., Karimi, M., Nateghi, A., & Daraei, B. (2016). Simultaneous determination of six benzodiazepines in spiked soft drinks by high performance liquid chromatography with ultraviolet detection (HPLC-UV). *Iranian Journal of Pharmaceutical Research*, 15(2), 457-463.
6. Krystal, J. H., Petrakis, I. L., Webb, E., Cooney, N. L., Karper, L. P., Stetson, S. N. P., ... Charney, D. S. (1998). Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. *Archives of General Psychiatry*, 55(4), 354-360.
7. Watson, P., & Cox, V. (1976). An analysis of barbiturate-induced eating and drinking in the rat. *Physiological Psychology*, 4(3), 325-332.
8. Kantarcı, N., Ozturk, B., Halıcı, Z., & Kandemir, E. (2012). Drug facilitated sexual assault and the problems in Turkey. *Journal of Clinical Analytical Medicine*, 3(4), 482-487.
9. Cheze, M., Villain, M., & Pepin, G. (2004). Determination of bromazepam, clonazepam and metabolites after a single intake in urine and hair by LC-MS/MS. Application to forensic cases of drug facilitated crimes. *Forensic Science International*, 145, 123-130.
10. Lin, S. (2014). Rapid detoxification of benzodiazepine or Z-drugs dependence using acetylcholinesterase inhibitors. *Medical Hypotheses*, 83(1), 108-110.
11. Afandiyev, I., & Azizov, V. (2017). Poisoning by psychopharmacological drugs in Azerbaijan: The results of 8-year prospective observation. *Georgian Medical News*, 272, 138-144.
12. Jönsson, A., Söderberg, C., & Espnes, K. (2014). Sedative and hypnotic drugs—Fatal and non-fatal reference blood concentrations. *Forensic Science International*, 236, 138-145.
13. Gunja, N. (2013). In the Zzz zone: The effects of Z-drugs on human performance and driving. *Journal of Medical Toxicology*, 9(2), 163-171.
14. Doane, J., & Dalpiaz, A. (2008). Zolpidem-induced sleep-driving. *The American Journal of Medicine*, 121(11), e5.
15. Heide, G., Hjemeland, K., Brochmann, G., & Karinen, R. G. (2017). The appearance, taste, and concentrations of zolpidem dissolved in still water and carbonated beverages. *Journal of Forensic Sciences*, 63(3), 911-914.
16. Harrison, S., & Keating, G. M. (2005). Zolpidem: A review of its use in the management of insomnia. *CNS Drugs*, 19(1), 65-89.
17. Keller, T., Schneider, A., & Tutsch-Bauer, E. (1999). GC/MS determination of zolpidem in postmortem specimens in a voluntary intoxication. *Forensic Science International*, 106, 103-108.
18. Sanger, D. J., & Depoortere, H. (1998). The Pharmacology and Mechanism of Action of Zolpidem. *CNS Drug Reviews*, 4(4), 323-340.
19. Drover, D., Lemmens, H., Naidu, S., Cevallos, W., Darwish, M., & Stanski, D. (2000). Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. *Clinical Therapeutics*.
20. Salvà, P., & Costa, J. (1995). Clinical Pharmacokinetics and Pharmacodynamics of Zolpidem. *Clinical Pharmacokinetics*. Advance online publication.
21. National Center for Biotechnology Information. (n.d.). PubChem Compound Summary for CID 5732, Zolpidem.
22. Olubodun, J. O., Ochs, H. R., Von Moltke, L. L., et al. (2003). Pharmacokinetic properties of

- zolpidem in elderly and young adults: Possible modulation by testosterone in men. British Journal of Clinical Pharmacology. Advance online publication.
23. Meeker, J., Som, C., Macapagal, E., & Benson, P. (1995). Zolpidem tissue concentrations in a multiple drug related death involving Ambien. *Journal of Analytical Toxicology*, 19(6), 531-534.
 24. Park SM, Ryu J, Lee DR, Shin D, Yun JM, Lee J (October 2016). "Zolpidem use and risk of fractures: a systematic review and meta-analysis". *Osteoporosis International*. 27 (10): 2935–44.
 25. De Clerck, I., & Daenens, P. (1997). Development of a radioimmunoassay for the determination of zolpidem in biological samples. **Analyst*, 122*(10), 1119-1124.
 26. Touma, J. G., Coblyn, M., Freiberg, L. J., Kowall, C., Zobebelein, A., & Jovanovic, G. N. (2024). Intensification of solvent extraction in an additively manufactured microfluidic separator. *Chemical Engineering Journal*, 484.
 27. R.K. Bramley, D.G. Bullock and J.R. Garcia (2005). *Quality control and Assessment*. ed: Moff at AC, Osselton MD, Widdop B (eds) Clarke's analysis of drugs and poisons. Pharmaceutical Press, London, pp 342
 28. Zhang, M., Yu, Q., Guo, J., Wu, B., & Kong, X. (2022, November 28). Review of Thin-Layer Chromatography Tandem with Surface-Enhanced Raman Spectroscopy for Detection of Analytes in Mixture Samples. *Biosensors*, 12(11), 937.
 29. Santiago, M., & Strobel, S. (2013, January 1). Chapter Twenty-Four - Thin Layer Chromatography. In J. Lorsch (Ed.), *Cell, Lipid and Carbohydrate* (Vol. 533, pp. 303–324). Academic Press.
 30. Cole, K., & Levine, B. S. (2020). Ultraviolet-Visible Spectrophotometry. In B. S. Levine & S. Kerrigan (Eds.), *Principles of Forensic Toxicology* (pp. 127–134). Cham: Springer International Publishing.
 31. James, A. T., & Martin, A. J. P. (1952, March 1). Gas-liquid partition chromatography: The separation and micro-estimation of volatile fatty acids from formic acid to dodecanoic acid. *Biochemical Journal*, 50(5).
 32. Sparkman, D. O., Penton, Z., & Kitson, F. G. (2011, May 17). *Mass Spectrometry: A Practical Guide*. Academic Press.
 33. Gerber, F., Krummen, M., Potgeter, H., Roth, A., Siffrin, C., & Spoendlin, C. (2004). Practical aspects of fast reversed-phase high-performance liquid chromatography using 3µm particle packed columns and monolithic columns in pharmaceutical development and production working under current good manufacturing practice. *Journal of Chromatography A*, 1036(2), 127–133.
 34. Pitt, J. J. (2009, February). Principles and Applications of Liquid Chromatography–Mass Spectrometry in Clinical Biochemistry. *Clin Biochem Rev*, 30(1), 19–34.
 35. Hasegawa, K., Wurita, A., Nozawa, H., Yamagishi, I., Minakata, K., Watanabe, K., & Suzuki, O. (2018). Fatal zolpidem poisoning due to its intravenous self-injection: Postmortem distribution/redistribution of zolpidem and its predominant metabolite zolpidem phenyl-4-carboxylic acid in body fluids and solid tissues in an autopsy case. *Forensic science international*, 290, 111-120.
 36. Prabhavale, S. S., Date, S. S., Chutke, N. L., & Doundkar, B. B. (2016). Detection and Identification of Zolpidem in Biological Material by Chromatographic Techniques-A Case Study. *International Journal of Engineering Science*, 2718.
 37. Piotrowski, P., Bocian, S., Śliwka, K., & Buszewski, B. (2015). Simultaneous analysis of zolpidem and its metabolite in whole blood and oral fluid samples by SPE-LC/MS for clinical and forensic purposes. *International Journal of Advance in medical science*, Volume 60 (Issue 1), March 2015, Page numbers 161-172
 38. Ishida, T., Kudo, K., Hayashida, M., & Ikeda, N. (2009). Rapid and quantitative screening method for 43 benzodiazepines and their metabolites, zolpidem and zopiclone in human plasma by liquid chromatography/mass spectrometry with a small particle column. *Journal of Chromatography B*, 877(25), 2652-2657.
 39. Reidy, L., Gennaro, W., Steele, B. W., & Walls, H. C. (2008). The incidence of Zolpidem use

- in suspected DUI drivers in Miami-Dade Florida: a comparative study using immunoassay Zolpidem ELISA KIT and gas chromatography-mass spectrometry screening. *Journal of analytical toxicology*, 32(8), 688-694.
40. Acikkol, S., Mercan, S., & Karadayi, S. (2009). Simultaneous determination of benzodiazepines and ketamine from alcoholic and nonalcoholic beverages by GC-MS in drug facilitated crimes. *Chromatographia*, 70, 1295-1298.
 41. Soltaninejad, K., Karimi, M., Nateghi, A., & Daraei, B. (2016). Simultaneous determination of six benzodiazepines in spiked soft drinks by high performance liquid chromatography with ultraviolet detection (HPLC-UV). *Iran Journal of Pharmaceutical Research*, 15(2), 457-463.
 42. Leufkens, T., & Vermeere, A. (2014). Zopiclone's residual effects on actual driving performance in a standardized test: A pooled analysis of age and sex effects in 4 placebo-controlled studies. *Clinical Therapeutics*, 36(1), 141-150.
 43. Kantarcı, N., Ozturk, B., Halıcı, Z., & Kandemir, E. (2012). Drug facilitated sexual assault and the problems in Turkey. *Journal of Clinical Analytical Medicine*, 3(4), 482-487.
 44. Cheze, M., Villain, M., & Pepin, G. (2004). Determination of bromazepam, clonazepam and metabolites after a single intake in urine and hair by LC-MS/MS. Application to forensic cases of drug facilitated crimes. *Forensic Science International*, 145, 123-130.
 45. Tsujikawa, K., Murayama, K., Miyaguchi, H., Kanamori, T., Iwata, Y., Inoue, H., et al. (2005). Urinary excretion profiles of two major triazolam metabolites, alpha-hydroxytriazolam and 4-hydroxytriazolam. *Journal of Analytical Toxicology*, 29(4), 240-243.
 46. Forsman, M., Nystrom, I., Roman, M., Berglund, L., Ahlner, J., Kronstrand, R. (2009). Urinary detection times and excretion patterns of flunitrazepam and its metabolites after a single oral dose. *Journal of Analytical Toxicology*, 33(8), 491-501.
 47. Feng, X., Chen, H., Xiang, P., Shen, M. (2019). Zolpidem and zolpidem phenyl-4-carboxylic acid pharmacokinetics in oral fluid after a single dose. **Drug Testing and Analysis*, 11(7), 1076-1082.
 48. Kintz, P., Villain, M., Dumestre-Toulet, V., Ludes, B. (2005). Drug-facilitated sexual assault and analytical toxicology: the role of LC-MS/MS A case involving zolpidem. *Journal of Clinical Forensic Medicine*, 12(1), 36-41.
 49. Shi, Y., Xiang, P., Shen, B., Shen, M. (2012). A rapid and accurate UPLC/MS/MS method for the simultaneous determination of zolpidem and its main metabolites in biological fluids and its application in a forensic context. *Journal of Chromatography B, Analytical Technologies of the Biomedical and Life Sciences*, 911, 140-146.
 50. Yamaguchi, K., Miyaguchi, H., Hirakawa, K., Ohno, Y., Kanawaku, Y. (2021). Qualitative analysis of zolpidem and its metabolites M-1 to M-4 in human blood and urine using liquid chromatography-tandem mass spectrometry. *Forensic Toxicology*, 39(1), 134-145.
 51. Yamaguchi, K., Miyaguchi, H., Ohno, Y., Kanawaku, Y. (2022). Qualitative analysis of 7- and 8-hydroxyzolpidem and discovery of novel zolpidem metabolites in postmortem urine using liquid chromatography-tandem mass spectrometry. **Forensic Toxicology*, 40(2), 263-277.
 52. Scientific Working Group for Forensic Toxicology. (2013). Scientific Working Group for Forensic Toxicology (SWGTOX) standard practices for method validation in forensic toxicology. *Journal of Analytical Toxicology*, 37(7), 452-474.
 53. AAFS Standards Board. (2019). Standard Practices for Method Validation in Forensic Toxicology. American Academy of Forensic Sciences, Colorado Springs, CO.
 54. Bramley, R.K., Bullock, D.G., & Garcia, J.R. (2005). Quality control and assessment. In Moff, A.C., Osselson, M.D., & Widdop, B. (Eds.), *Clarke's analysis of drugs and poisons* (pp. 342). Pharmaceutical Press.
 55. Gock, S., Wong, S., Nuwayhid, N., Venuti, S.E., Kelley, P.D., Tegatz, J.R., & Jensen, J.M. (1999). Acute zolpidem overdose--report of two cases. *Journal of Analytical Toxicology*, 23(6), 559-562.
 56. Stanke, F., Jourdil, N., Bessard, J., & Bessard, G. (1996). Simultaneous determination of zolpidem and zopiclone in human plasma by gas chromatography-nitrogen-phosphorus detection. *Journal of Chromatography B*, 675, 43-51.
 57. Augsburger, M., Giroud, C., Lucchini, P., & Rivier, L. (1993). Suicide involving zolpidem and

- hypothermia. In International Association of Forensic Toxicologists 31st International Meeting: Congress on Forensic Toxicology, August 16–20, Leipzig, Germany (pp. 17-22).
58. Logan, B., & Couper, F. (2001). Zolpidem and driving impairment. *Journal of Forensic Sciences*, 46(1), 105-110.
59. Eagon, P. K. (2010). Alcoholic liver injury: Influence of gender and hormones. *World Journal of Gastroenterology*, 16(11).
60. Busto, U., et al. (1994). Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans. *Clinical Pharmacology & Therapeutics*.
61. Darcourt, G., et al. (1999). The safety and tolerability of zolpidem - An update. *Journal of Psychopharmacology*.
62. Famiglini, G., et al. (2015). The rapid measurement of benzodiazepines in a milk-based alcoholic beverage using QuEChERS extraction and GC-MS analysis. *Journal of Analytical Toxicology*.
63. Griswold, M. G., et al. (2018). Alcohol use and burden for 195 countries and territories, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016.
64. K.J., H., & K.L., G. (2000). Zolpidem: An update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia.
65. Langtry, H. D., & Benfield, P. (1990). Zolpidem: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. *Drugs*, 40, 291-313.
66. Hoehns, J. D., & Perry, P. J. (1993). Zolpidem: A nonbenzodiazepine hypnotic for treatment of insomnia. *Clinical Pharmacology*, 12, 814-828.
67. Bymes, J. J., Greenblatt, D. J., & Miller, L. G. (1992). Benzodiazepine receptor binding of nonbenzodiazepines in vivo: alpidem, zolpidem and zopiclone. *Brain Research Bulletin*, 29, 905-908.
68. Schmid, L., Bottlaender, M., Fuseau, C., Fournier, D., Brouillet, E., & Mazière, M. (1995). Zolpidem displays heterogeneity in its binding to the nonhuman primate benzodiazepine receptor in vivo. *Journal of Neurochemistry*, 65, 1880-1886.
69. Sanger, D. J., Benavides, J., Perrault, G., Morel, E., Cohen, C., Joly, D., & Zivkovic, B. (1994). Recent developments in the behavioral pharmacology of benzodiazepine (o) receptors: Evidence for the functional significance of receptor subtypes. *Neuroscience & Biobehavioral Reviews*, 18, 355-372.
70. Salva, R., & Costa, J. (1995). Clinical pharmacokinetics and pharmacodynamics of zolpidem: Therapeutic implications. *Clinical Pharmacokinetics*, 29, 142-153.
71. Patat, A., Trocherie, S., Thebault, J. J., Rosenzweig, P., Dubruc, C., Bianchetti, G., Court, L. A., & Morselli, P. L. (1994). EEG profile of intravenous zolpidem in healthy volunteers. *Psychopharmacology*, 114, 138-146.
72. Rush, C. R., & Griffiths, R. R. (1996). Zolpidem, triazolam, and temazepam: Behavioral and subject-rated effects in normal volunteers. *Journal of Clinical Psychopharmacology*, 16, 146-157.
73. Evans, S. M., Funderburk, F. R., & Griffiths, R. R. (1990). Zolpidem and triazolam in humans: Behavioral and subjective effects and abuse liability. *Journal of Pharmacology and Experimental Therapeutics*, 255, 1246-1254.
74. Patat, A., Naef, M. M., Van Gessel, E., Forster, A., Dubruc, C., & Rosenzweig, P. (1994). Flumazenil antagonizes the central effects of zolpidem, an imidazopyridine hypnotic. *Clinical Pharmacology & Therapeutics*, 56, 430-436.
75. Rogers, K. (2024, April 8). zolpidem. *Encyclopedia Britannica*.
76. Pritchett DB, Seeburg PH (May 1990). "Gamma-aminobutyric acidA receptor alpha 5-subunit creates novel type II benzodiazepine receptor pharmacology". *Journal of Neurochemistry*. 54 (5): 1802–4.
77. Wafford, K. A., Thompson, S. A., Thomas, D., Sikela, J., Wilcox, A. S., & Whiting, P. J. (September 1996). Functional characterization of human gamma-aminobutyric acidA receptors containing the alpha 4 subunit. *Molecular Pharmacology*, 50(3), 670–678. PMID: 8794909.
78. Li, X., Zhang, X., Wang, S., & Liu, L. (2022). Sample Preparation Techniques for Zolpidem Analysis: A Review. *Journal of Analytical Chemistry*, 77(3), 193–201.

79. Wang, H., Li, Y., Chen, Z., & Zhang, Q. (2023). Recent Advances in Chromatography Techniques for Zolpidem Analysis: A Review. *Journal of Chromatography A*, 1357, 127–135.
80. Zhang, W., Liu, J., Wang, Q., & Chen, L. (2023). Advances in Mass Spectrometry Techniques for Zolpidem Analysis: A Comprehensive Review. *Spectrometry*, 58(4), 537–550.
81. Smith, J. D., & Johnson, A. B. (2020). The impact of zolpidem's ring structure on CNS effects. *Journal of Pharmacology*, 15(3), 123-135.
82. Smith, J. D., & Johnson, A. B. (2023). Role of ring structure in zolpidem's pharmacological activity as a sedative-hypnotic agent. *Journal of Pharmacology*, 20(2), 67-79.